On August 21, 2026 AbbVie (NYSE: ABBV) reported new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker identification that may help inform future research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Our strategy in lung cancer is focused on building a complementary pipeline that brings together next-generation immunotherapies and targeted antibody-drug conjugates with the potential to address different aspects of tumor biology," said Daejin Abidoye, M.D., vice president and therapeutic area head of oncology, solid tumor and hematology at AbbVie. "Exploring the PD-1/VEGF approach represented by ABBV-1480 and the c-Met targeting by Temab-A are important elements of that strategy and may provide a foundation for potential novel combinations as we work to develop more tailored treatment approaches for people living with lung cancer."
Advancing Novel Therapies Across Various Modalities in NSCLC
Multiple presentations across AbbVie’s NSCLC portfolio will showcase new studies and data analyses spanning multiple treatment modalities, highlighting first-line treatment approaches, patient experience and biomarker-informed research.
ABBV-1480 (RC148): AbbVie, in partnership with RemeGen, will present Phase 1b data evaluating the investigational PD-1/VEGF bispecific antibody, ABBV-1480, in combination with platinum-based chemotherapy as a potential first-line treatment for advanced NSCLC. At the 10 mg/kg dose, identified as the recommended Phase 3 dose for further development in combination regimens in both squamous and non-squamous NSCLC, the primary endpoint of objective response rate (ORR) was 90.0% in squamous NSCLC (n=27/30) and 75.9% (n=22/29) in non-squamous NSCLC. The most common treatment-related adverse events (TRAEs) were a decrease in white blood cells, neutrophil, platelet counts and anemia. No grade ≥3 hemorrhages with the 10 mg combinations were observed. This overall manageable safety profile supports ongoing Phase 3 development for this novel investigational asset.1
Telisotuzumab adizutecan (Temab-A), an investigational c-Met-directed ADC with a topoisomerase 1 inhibitor (Top1i) payload: Building on encouraging preliminary activity2 observed in heavily pretreated patients, AbbVie initiated a Phase 1b/2 M24-536 study (NCT06772623). The study is evaluating a platinum-free combination of Temab-A and a PD-1 inhibitor, as a potential first-line treatment for advanced non-squamous NSCLC. The study includes analyses of c-Met and PD-L1 expression to identify the patients most likely to benefit from treatment.3 Temab-A is also being studied in epidermal growth factor receptor (EGFR)-mutated NSCLC as monotherapy or in combination with osimertinib (NCT07155187).
Clinical Data Showcasing the Potential of ABBV-706 in SCLC
ABBV-706 is an investigational SEZ6-targeted ADC with a Top1i payload, being evaluated in SCLC. Presentations at WCLC include research that further characterizes the program and the potential role of SEZ6 in SCLC.
As previously reported, ABBV-706 demonstrated an ORR of 82% in patients with relapsed/refractory SCLC post platinum-based chemotherapy (n=17).4 New safety analyses from 240 patients who received ABBV-706 monotherapy showed generally manageable hematologic and gastrointestinal toxicities, with the most common gastrointestinal events, including nausea (35.8%), vomiting (17.5%) and diarrhea (10.8%), being largely low grade and most requiring no dose adjustments.5 Grade ≥3 treatment-related pneumonitis or interstitial lung disease was reported in 1.7% of patients receiving ABBV-706 monotherapy.6 Hematologic toxicities, including anemia, neutropenia and thrombocytopenia, were among the most common TRAEs.5 Serious TRAEs occurred in 12.5% of patients. ABBV-706 is being evaluated as monotherapy in a Phase 3 study (NCT07365241) and in combination with atezolizumab in the Phase 2 study (NCT07155174), in SCLC.
Real-world research demonstrated that SEZ6 is broadly expressed in 91% of SCLC patients overall and in more than 96% of patients with brain or liver metastases. These findings further support SEZ6 as a potential therapeutic target in SCLC and other SEZ6-expressing tumors. 7
Additional details on key presentations are available below, and the full WCLC 2026 abstracts are available online.
For information about AbbVie’s clinical trial efforts in lung cancer, please visit clinicaltrials.gov.
Title
Date/Time
Session
Abstract Number
Radiomic Biomarkers on Baseline CT
Scans for Predicting Response to
Teliso-V in NSCLC: A Machine
Learning Approach
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.077-248.
Pathology and
Biomarkers
P2.137.
Telisotuzumab Adizutecan and PD-1 Inhibitor
in Untreated Advanced Non-Squamous
Non-Small Cell Lung Cancer: A Phase
1b/2 Study
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.304-390.
Clinical Trials in
Progress
P2.374.
Efficacy and Safety of ABBV-706 Versus
Standard of Care in Relapsed/Refractory
Small Cell Lung Cancer: A Phase 3 Study
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.304-390.
Clinical Trials in
Progress
P2.377.
A Phase 3, Randomized, Double-Blind Trial
of RC148 (ABBV-1480) Plus Chemotherapy
in First-Line Squamous Non-Small-Cell
Lung Cancer
Monday,
September 14
10:30AM-12:00PM KST
Poster
Session: P2.304-390.
Clinical Trials in
Progress
P2.379.
Peripheral Neuropathy With Teliso-V in
c-Met- Protein Overexpressing NSCLC
in LUMINOSITY: Clinical Characteristics
and PROs
Monday,
September 14
2:17-2:25 PM KST
Poster
Session: PT2.01.
Metastatic
NSCLC –
Antibody-Drug
Conjugate and
Cytotoxic
Therapy
PT2.01.05.
Telisotuzumab vedotin Demonstrates Potent
Antitumor Efficacy in Preclinical Models of
Diffuse Pleural Mesothelioma
Monday,
September 14
2:17-2:25 PM KST
Poster
Session: PT2.05.
Mesothelioma,
Thymoma, and
Other Thoracic
Tumors
PT2.05.05.
Hematologic and Gastrointestinal Toxicity of
ABBV-706 in Advanced Solid Tumors: Safety
Profile from the First-in-Human Study
Tuesday,
September 15
9:30-11:00 AM KST
Poster
Session: P3.282-354.
Small Cell Lung
Cancer and
Neuroendocrine
Tumors
P3.316.
SEZ6 Is Expressed Across Major Clinical and
Demographic Groups of SCLC Patients:
Evidence From a US Clinicogenomic
Database
Tuesday,
September 15
9:30 AM-11:00 AM KST
Poster
Session: P3.282-354.
Small Cell Lung
Cancer and
Neuroendocrine
Tumors
P3.340.
RC148 (ABBV-1480, PD-1/VEGF Bispecific
Antibody) Plus Chemotherapy in First-Line
Locally Advanced or Metastatic Non-Small-
Cell Lung Cancer
Tuesday,
September 15
12:52-1:02 PM KST
Oral Presentation
Session: OA14.
The Breakthrough
Immunotherapy
for Advanced
NSCLC
OA14.01.03.
High Burden and Limited Evidence in Late-
Line ES-SCLC: A Structured Review of
Clinical and Humanistic Outcomes
E-Poster
EP13 Small Cell
Lung Cancer and
Neuroendocrine
Tumors
EP13.05.
Pneumonitis/Interstitial Lung Disease in the
First-in-Human ABBV-706 Study: Incidence,
Management, and Risk Factors
E-Poster
EP13 Small Cell
Lung Cancer and
Neuroendocrine
Tumors
EP13.32.
Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.
AbbVie holds exclusive rights from RemeGen to develop, manufacture, and commercialize ABBV-1480 outside of the Greater China territory.
Emrelis (telisotuzumab vedotin-tllv) is an approved medicine being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.
(Press release, AbbVie, AUG 21, 2026, View Source [SID1234670272])